29
Aug 2026
Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
29
Aug 2026
A registry-based digital strategy that identified untreated patients and invited them to a telephone consultation more than doubled implementation of an effective type of heart failure treatment.
29
Aug 2026
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment.
29
Aug 2026
Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
29
Aug 2026
Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.
29
Aug 2026
Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.
29
Aug 2026
Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
29
Aug 2026
Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.
29
Aug 2026
Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
29
Aug 2026
Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to results from the REACT study presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
